Engineering Approaches to Modify Mesenchymal Stromal Cell (MSC) Immunomodulatory Functions: Advancing Tissue Regeneration and Clinical Application via iPSC-Derived MSCs, Cell Pre-treatment, and EV Therapeutics

August 17, 2026

PMC International

Overview

Engineering approaches to modify mesenchymal stromal cell (MSC) immunomodulatory functions are crucial for tissue regeneration and clinical applications. These strategies include cell pre-treatment and genetic modification to improve therapeutic efficacy, biomaterial-mediated delivery systems for targeted sites, MSC-derived extracellular vesicle (EV) based therapeutics to amplify paracrine signals, and the use of iPSC-derived MSCs to overcome donor variability. These innovations enhance the efficacy and safety of MSC-based therapies, enabling broader application across various diseases.

In Depth

Key Findings

Diverse engineering approaches to modify the immunomodulatory functions of mesenchymal stromal cells (MSCs) are driving pivotal advancements in tissue regeneration and clinical applications. These innovative strategies aim to optimize the therapeutic efficacy of MSCs and broaden their utility, with the potential to overcome existing challenges such as donor variability and limited expansion capacity.

Technical & Clinical Details

Cell Pre-treatment and Genetic Modification: To enhance the therapeutic efficacy of MSCs, strategies include cell pre-treatment (e.g., cytokine priming, hypoxic preconditioning) and genetic modification (e.g., overexpression of specific therapeutic genes or immunomodulatory molecules). These interventions are designed to improve MSC survival, homing capabilities to injury sites, and overall immunomodulatory activity.
Biomaterial-Mediated Targeted Delivery Systems: Combining MSCs with biomaterials (e.g., hydrogels, microcarriers) can facilitate cell survival and enable localized delivery and long-term retention at target sites. This approach increases the likelihood that therapeutic cells efficiently reach the intended tissue and exert their beneficial effects, enhancing the therapeutic window.
MSC-Derived Extracellular Vesicle (EV)-Based Therapeutics: Extracellular vesicles (e.g., exosomes) secreted by MSCs are crucial mediators of MSCs’ paracrine effects (acting on nearby cells). Utilizing EVs as therapeutic agents can leverage the therapeutic benefits of MSCs while circumventing risks associated with cell transplantation itself (e.g., tumor formation, immunogenicity). Engineered EVs can further enhance targeted delivery and amplify therapeutic effects for specific indications.
iPSC-Derived MSCs: Donor-derived MSCs present challenges such as inter-donor variability and limited proliferative capacity. MSCs induced from induced pluripotent stem cells (iPSCs) offer a promising solution to these issues, as they can proliferate indefinitely and establish consistent, well-characterized cell lines. This approach facilitates product standardization and large-scale manufacturing, crucial for commercial development.

Background & Industry Context

MSCs have attracted significant attention as treatments for a wide range of diseases, including autoimmune disorders, inflammatory conditions, ischemic diseases, and tissue injuries, due to their immunomodulatory properties, multipotent differentiation capacity, and tissue repair capabilities. However, the efficacy of MSC therapy can vary depending on cell origin, culture conditions, and patient characteristics. Engineering approaches are being developed to reduce this variability and consistently enhance therapeutic outcomes, driving towards more reliable clinical applications.

Strategic Significance & Outlook

These engineering approaches for modifying MSC immunomodulatory functions hold the potential to dramatically improve the efficacy and safety of MSC-based therapies in tissue regenerative medicine and clinical applications. The introduction of iPSC-derived MSCs will enable product standardization and large-scale manufacturing, thereby broadening patient access. The development of EV-based therapeutics opens new frontiers in cell-free therapy, alleviating logistical and safety challenges associated with cell transplantation. These technological innovations are expected to accelerate the clinical success of MSC therapies across a broad spectrum of disease areas, including inflammatory, autoimmune, cardiovascular, and neurodegenerative diseases.

Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC13325650/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.